Namita Thapar is set to earn good returns from Emcure Pharmaceuticals’ upcoming IPO. According to the company’s red herring prospectus, Thapar will earn a 293-fold return on her initial investment by partially offloading her stake. Return on Investment At the upper end of the price band, Thapar will see her investment multiply 293 times. The …

